Summary of recent important research progress in the treatment of stomach cancer

The combination of L1 methylation and tumor-immersed lymphocytes can be used as a prognosis for advancedgastric cancer, the researchers used CD3immuno
tissue chemistry and pyrophosphate sequencing methylation analysis, respectively, to measure THE TIL and tumor L1 methylation levels in advanced GC samples (n s 491)The TIL density is measured in the tumor center and the immersion areaIt was found that TIL density was associated with tumor L1-methylation level, but the relationship was weakThe researchers found that the combined state of L1 methylation level and CD3 TIL density was statistically significant in survival analysisMultivariate analysis shows that the relationship between combined states and survival is independentIn a separate group, the prognosis value of invasive front-line combination states was significantIt was shown that tumor L1 methylation levels were associated with TIL density2Pym sabuta-combined therapy first-line treatment of HER2-positive metastatic esophageal gastric canceradding quertallin monotoresis to first-line chemotherapy can improve the overall survival rate of PATIENTs with HER2-positive metastatic gastric cancerRecently, researchers evaluated the efficacy of pymmonotag, qurillazumab and combined first-line chemotherapy in her2-positive metastatic esophageal (gastric, esophagus, or gastroesophageal junction) cancerThe study included the participation of patients aged 18 years or older with HER2-positive metastatic esophageal gastric cancer, starting with 200mg pym monotom and 8 mg/kg querceon monotolita induction therapy Subsequently, the patient received 130 mg/m 2 of oshari platinum or 80 mg/m 2 of cisplatin treatment on the first day, twice daily oral kapitabin 850 mg/m 2, for 2 weeks, 1 week apart, on the first day of each 3 weeks, intravenous injection of 200 mg pym monosar and 6 mg/kg of querotium monotoplasm As a result, 26 (70%) of the 37 patients did not progress at 6 months The most common adverse event of any level of treatment is neuropathy (97%) The most common adverse events of level 3 or 4 are lymphocyte reduction, level 3 electrolyte reduction, and level 3 anemia Two patients had severe adverse events Four patients discontinued use of pymzumab due to adverse immune-related reactions There were no treatment-related deaths It was shown that pym monotometreath and qural-bead monotherapy combined chemotherapy could effectively prolong the non-progressive survival of PATIENTs with HER2-positive metastatic esophageal cancer surgery alone is sufficient to treat the of T1 gastric cancer with extensive lymph node metastasis
whether individual surgeries are sufficient to treat patients with T1N2M0 (IIA), T1N3a/bM0 (IIB/IIIB) and T3N0M0 (Phase IIA) stomach cancer This study aims to explore this possibility The researchers reviewed the clinical records of 236 patients diagnosed at the National Cancer Center Hospital in Japan from January 2000 to December 2012 236 patients diagnosed with pT1N2-3b/pT3N0 gastric cancer and r0 gastric resection and lymph node swept The results showed that the five-year non-recurrence survival rate (RFS) of patients with T1N2-3b and T3N0 cancer was 73.9% and 89.5%, respectively The only important prognosis factors for the survival of pT1N2-3 cancer patients determined by multifactory Cox regression analysis were pN staging and tumor diameter Using these two important prognostic factors, pT1N2-3 gastric cancer patients were divided into 3 risk categories and significantly different rates of RFS over 5 years were found between the three risk groups It indicates that the prognosis of pT3N0 and large pT1N2 with diameters of 30 mm is good, while the prognosis of pT1N2-3 with a diameter of at least N3a/b or tumor diameter of 30 mm is relatively poor serum ANOS1 level can be used as a biomarker for the diagnosis of stomach cancer
the development of high-performance serum biomarkers may improve the prognosis of patients with stomach cancer (GC) The researchers conducted a forward-looking multicenter observational study designed to verify the diagnosis of the properties of potential markers such as anosmin 1 (ANOS1), dihydropyrimidinase-like 3 (DPYSL3) and melanoma-related antigen D2 (MAGE-D2) The researchers analyzed serum levels before and after surgery on three potential biomarkers in GC patients and healthy volunteers Serum and GC tissue levels were quantified using ELISA Correlation analysis was carried out The results showed that the under-curve area (AUC) values of GC patients and health control were ANOS1, DPYSL3 and MAGED2 were -0.7058, 0.6188 and 0.5031 The sensitivity and specificity of ANOS1 analysis are 0.36 and 0.85, respectively AUC value of ANOS1, which distinguishes IGC patients from health control, is 0.7131 Compared to the health control group, serum ANOS1 levels increased significantly in patients with stage I GC and decreased after the removal of primary GC lesions The combination of serum ANOS1 and DPYSL3 levels increased AUC values, separating GC patients from healthy controls Serum ANOS1 levels were not significantly correlated with cancer embryo antigens, carbohydrate antigens 19-9 or other inflammatory markers It is shown that the level of serum ANOS1 can be used as an excellent diagnostic tool for management GC the efficacy of local advanced gastric cancer in the far end of laparoscopic surgery after new assisted chemotherapy laparoscopic far-end gastric excision and new assisted chemotherapy are increasingly used to treat local advanced gastric cancer However, the safety and effectiveness of laparoscopic surgery after the new assisted chemotherapy is not clear Therefore, the purpose of this study is to assess the immediate prognosis of patients with local advanced gastric cancer who underwent laparoscopic far-end gastric resection or open far-end gastric resection From April 23, 2015 to November 16, 2017, the researchers conducted a Phase 2, open-label, non-effective randomized clinical trial at the Gastrointestinal Oncology Center at Peking University Cancer Hospital in China Patients with localadvanced gastric cancer (cT2-4aN plus M0) between the ages of 18 and 80 who received new complementary chemotherapy (n s 96) A total of 95 patients met the conditions of treatment analysis, the results showed that the incidence of postoperative complications in the LADG group was significantly lower than that of the ODG group In the LADG group alone, the visual simulation scale score for pain in 2 days after surgery was reduced by 1.2 units only 2 days after surgery Patients in the LADG group had a better completion rate of complementary chemotherapy and were less likely to terminate complementary chemotherapy due to adverse reactions In summary, the trial found that LADG appeared to have better postoperative safety and auxiliary chemotherapy tolerance for patients with local advanced gastric cancer who underwent new assisted chemotherapy than ODG Source: MedSci Original